Vivani Medical, Inc. (VANI)

NASDAQ: VANI · Real-Time Price · USD
1.290
0.00 (0.00%)
Nov 20, 2024, 4:00 PM EST - Market closed
0.00%
Market Cap 71.28M
Revenue (ttm) n/a
Net Income (ttm) -23.46M
Shares Out 55.26M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 128,297
Open 1.290
Previous Close 1.290
Day's Range 1.280 - 1.340
52-Week Range 0.840 - 7.800
Beta 3.51
Analysts Strong Buy
Price Target 3.00 (+132.56%)
Earnings Date Nov 13, 2024

About VANI

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an e... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 19, 2014
Employees 44
Stock Exchange NASDAQ
Ticker Symbol VANI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for VANI stock is "Strong Buy" and the 12-month stock price forecast is $3.0.

Price Target
$3.0
(132.56% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-acting drug implants, today reported financ...

7 days ago - Business Wire

Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, ann...

4 weeks ago - Business Wire

Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today ann...

2 months ago - Business Wire

Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, ann...

2 months ago - Business Wire

Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal drug impla...

2 months ago - Business Wire

Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal drug impla...

3 months ago - Business Wire

Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-acting drug implants, today reported financ...

3 months ago - Business Wire

Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, long-term drug implants, today announced t...

4 months ago - Business Wire

Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, long-term drug implants, today announced t...

5 months ago - Business Wire

Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset...

6 months ago - Business Wire

Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset...

6 months ago - Business Wire

Vivani Medical to Present at TIDES Conference 2024

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset...

7 months ago - Business Wire

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset...

8 months ago - Business Wire

Vivani Medical Appoints Daniel Bradbury to its Board of Directors

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants,...

9 months ago - Business Wire

Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants,...

9 months ago - Business Wire

Vivani Medical (VANI) stock price surged: is it a good buy?

Vivani Medical (NASDAQ: VANI) stock price surged hard this week after the company published positive results of its ongoing weight loss drug trial. The shares surged from about $1 and reached a high o...

9 months ago - Invezz

Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants,...

9 months ago - Business Wire

Vivani Medical Provides Business Update and Reports Third Quarter Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants,...

1 year ago - Business Wire

Vivani Medical to Present at BIO Investor Forum

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, preclinical-stage biopharmaceutical company that develops novel, long-term drug implan...

1 year ago - Business Wire

Vivani Medical to Present at the Boulder Peptide Symposium

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, preclinical-stage biopharmaceutical company that develops novel, long-term drug implan...

1 year ago - Business Wire

Vivani Medical Subsidiary Cortigent to Present Orion Clinical Study Results at The Eye and The Chip World Research Congress on Artificial Vision October 8-10

EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, announced today that its...

1 year ago - Business Wire

Vivani Medical Reports Second Quarter Financial Results and Provides Business Update

EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implan...

1 year ago - Business Wire

Vivani Medical, Inc. Subsidiary Cortigent Reports 5-Year Early Feasibility Study Update for the Orion® Visual Cortical Prosthesis System

EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI), an innovative, near-clinical stage biopharmaceutical company that is developing novel, miniature, long-term therapeutic implan...

1 year ago - Business Wire

Vivani Medical to Participate in Panel Discussion at the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, near clinical-stage biopharmaceutical company that develops novel, miniature, long-...

1 year ago - Business Wire

Vivani Medical Reports First Quarter Financial Results and Provides Business Update

EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants, including lead produ...

1 year ago - Business Wire